Imeik Technology Development Co.,Ltd.
300896
Rang in aandelen
#3834
Imeik Technology Development Co.,Ltd. specializes in the research, development,... Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.
Aandeelprijs
$14.36
Marktkapitalisatie
$4.35B
Verandering (1 dag)
0.22%
Verandering (1 jaar)
-39.05%
Land
CN
Handel Imeik Technology Development Co.,Ltd. (300896)
Categorie
Healthcare
P/B-ratio voor Imeik Technology Development Co.,Ltd. (300896)
P/B-ratio op October 2026 TTM: 3.60
Volgens de meest recente financiële rapporten en aandelenkoers van Imeik Technology Development Co.,Ltd. is de huidige P/B-ratio (TTM) 3.60. Eind 2023 had het bedrijf een P/B-ratio van 9.74.
P/B-ratiohistoriek voor Imeik Technology Development Co.,Ltd. van 2014 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 3.60 | -48.89% |
| 2024 | 7.05 | -27.60% |
| 2023 | 9.74 | -34.97% |
| 2022 | 14.97 | -9.12% |
| 2021 | 16.47 | 32.81% |
| 2020 | 12.40 | -72.01% |
| 2019 | 44.31 | -18.96% |
| 2018 | 54.68 | -18.99% |
| 2017 | 67.50 | -15.17% |
| 2016 | 79.56 | -42.30% |
| 2015 | 137.90 | -41.94% |
| 2014 | 237.50 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 8.1997 | 127.55% |
US
|
|
| 1.7417 | -51.67% |
FR
|
|
| - | - |
JP
|
|
| 2.1258 | -41.01% |
US
|
|
| - | - |
CH
|
